SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > Canadian > Biotechs >

Immuno Vaccine Inc. (IMMVF)

IMMVF RSS Feed
Add IMMVF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/16/2017 11:56:28 AM - Followers: 5 - Board type: Free - Posts Today: 0

TSX-V: IMV Immunovaccine is a biotechnology company focused on advancing cancer therapies and infectious disease vaccines based on its patented immune enhancement platform DepoVaxTM Highlights Advance cancer immune therapies designed to maintain patients in remission and improve survival Develop differentiated infectious disease vaccines to address unmet medical threats Leverage DepoVaxTM as a potent and flexible product enabling platform through technology licenses and partnerships Product Pipeline Immunovaccine’s Patented Technology DepoVaxTM is a vaccine delivery platform that creates a unique deposit at the site of injection. This forces the immune system to process the optimized vaccine over a longer period of time, producing strong and sustained immunity. Immunovaccine develops products based on this platform and licenses the use of the platform to other parties for specific applications. Cancer Immunotherapy Immune based therapies are expected to form the backbone of cancer treatments in the next decade. IMV’s lead cancer immune therapy DPX-Survivac is an immunotherapy designed to train CD8+ T cells of the immune system to recognize cancer cells containing survivin, a therapeutic target associated with the great majority of solid tumors and blood cancers. Our therapy has demonstrated robust and sustained CD8+ T cell responses against survivin in a Phase 1 trial with evidence of a clinical benefit that is potentially associated with the therapy. We are planning two large randomized Phase 2 clinical trials in ovarian cancer and glioblastoma. Infectious disease vaccines Having demonstrated the ability to produce rapid, strong and sustained immunity against several disease models, Immunovaccine has attracted government agencies and research organizations to apply the DepoVax technology to create new and improved infectious disease vaccines. A Respiratory Syncytial Virus (RSV) vaccine designed to protect the elderly from the deadly illness will begin clinical testing in 2014; a counter bioterrorism vaccine for Anthrax has shown the potential for single dose applicability in studies performed by the US National Institutes of Health. These vaccine candidates represent significant future commercial opportunities for IMV. Immunovaccine’s Patented Technology DepoVaxTM is a vaccine delivery platform that creates a unique deposit at the site of injection. This forces the immune system to process the optimized vaccine over a longer period of time, producing strong and sustained immunity. Immunovaccine develops products based on this platform and licenses the use of the platform to other parties for specific applications. Cancer Immunotherapy Immune based therapies are expected to form the backbone of cancer treatments in the next decade. IMV’s lead cancer immune therapy DPX-Survivac is an immunotherapy designed to train CD8+ T cells of the immune system to recognize cancer cells containing survivin, a therapeutic target associated with the great majority of solid tumors and blood cancers. Our therapy has demonstrated robust and sustained CD8+ T cell responses against survivin in a Phase 1 trial with evidence of a clinical benefit that is potentially associated with the therapy. We are planning two large randomized Phase 2 clinical trials in ovarian cancer and glioblastoma. Infectious disease vaccines Having demonstrated the ability to produce rapid, strong and sustained immunity against several disease models, Immunovaccine has attracted government agencies and research organizations to apply the DepoVax technology to create new and improved infectious disease vaccines. A Respiratory Syncytial Virus (RSV) vaccine designed to protect the elderly from the deadly illness will begin clinical testing in 2014; a counter bioterrorism vaccine for Anthrax has shown the potential for single dose applicability in studies performed by the US National Institutes of Health. These vaccine candidates represent significant future commercial opportunities for IMV.  Management Albert Scardino Executive Chairman Marc Mansour, PhD Chief Operating Officer Kimberly Stephens, CA Chief Financial Officer Additional DepoVaxTM platform opportunities Immunovaccine’s core technology is versatile and can be applied to vaccines against a broad range of diseases. The commercial license agreements with Zoetis (formerly Pfizer Animal Health) and the high profile research partnerships in place are a testament to the differentiation the DepoVaxTM technology provides.
IMMVF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PostSubject
#61   Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored xr_biotech_consult 05/16/17 11:56:28 AM
#60   EPS for ImmunoVaccine Inc. (IMV) Expected At $-0.02 John-Knee 05/04/17 10:24:12 PM
#59   ImmunoVaccine Inc. (IMV) Insider Buys C$10,800.00 in Stock John-Knee 05/04/17 07:04:25 AM
#58   Immunovaccine to Present at 19th Annual TIDES: Oligonucleotide John-Knee 05/02/17 07:20:16 AM
#57   Biotech Stock Immunovaccine At All-Time High, Breaking Out John-Knee 04/30/17 06:25:17 AM
#56   moving2newhighs :-) xr_biotech_consult 04/28/17 10:43:51 AM
#55   Insiders are buying consistently these past few weeks. John-Knee 04/25/17 07:14:59 PM
#54   Announces Dosing of First Patient in Investigator-Sponsored Phase xr_biotech_consult 04/18/17 10:44:32 AM
#53   Positive Year-Long Immunogenicity Data from Phase 1 Clinical xr_biotech_consult 04/12/17 02:08:00 PM
#52   Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored xr_biotech_consult 02/06/17 10:06:54 AM
#51   Hello! Is there anybody here? You'd think this Bugzzie75 07/22/16 11:52:20 AM
#50   a critical milestone for Immunovaccine, xr_biotech_consult 07/06/16 11:42:51 AM
#49   great News out: xr_biotech_consult 07/06/16 11:41:37 AM
#48   Initiates Zika Virus Vaccine Program xr_biotech_consult 03/03/16 12:43:02 PM
#47   soon knocks da 1$ xr_biotech_consult 07/20/15 12:53:31 PM
#46   its not an approval. Receives Orphan Drug Designation xr_biotech_consult 07/15/15 03:29:05 PM
#45   FDA APPROVAL wab2021 07/15/15 11:20:56 AM
#44   tiny little gem here, main listening is at xr_biotech_consult 07/08/15 12:29:18 PM
#43   Albert Scardino of Immunovaccine Inc. : xr_biotech_consult 07/08/15 12:27:09 PM
#42   IMMUNOVACCINE AND PHARMATHENE SIGN EXCLUSIVE WORLDWIDE LICENSE AGREEMENT xr_biotech_consult 07/08/15 12:24:20 PM
#41   Immunovaccine releases DPX-Survivac clinical results xr_biotech_consult 07/08/15 12:23:11 PM
#40   Immunovaccine Initiates Clinical Trial with DPX-RSV Vaccine xr_biotech_consult 07/08/15 12:21:59 PM
#39   Incyte and Immunovaccine team up in ovarian cancer xr_biotech_consult 07/08/15 12:20:04 PM
#38   L2's are thin. It has great potential. Sunnyjoe234 05/18/15 01:37:03 PM
#37   Seel, Please do let us know what someconcerns 03/06/14 07:55:42 PM
#36   Well that is intriguing. I think I need Seel 03/05/14 06:16:26 PM
#35   One trade, 50k. Somebody is buying all noretreat 03/05/14 01:18:53 PM
#34   Well that is certainly true. I am not Seel 03/04/14 07:19:14 PM
#33   But, then again with a volume of 4K Ovidius 03/04/14 02:47:39 AM
#32   That is quite a spike. I can't find Seel 03/03/14 06:54:02 PM
#31   Someone just picked up my shares for a noretreat 03/03/14 10:10:49 AM
#30   Oh my god - you are cracking me up! Seel 02/21/14 08:35:16 PM
#29   I would not want anyone to get the noretreat 02/21/14 07:07:28 PM
#28   No worries noretreat! It was a funny comment! Seel 02/21/14 07:01:46 PM
#27   That was not a serious comment, just in noretreat 02/21/14 06:53:40 PM
#26   I always (ALWAYS!) chase the women who think noretreat 02/21/14 06:29:10 PM
#25   Think you're going to get away from us Seel 02/21/14 04:59:01 PM
#24   There was a pending article by GratefulLife which TOB 02/21/14 04:12:54 PM
#23   Oh for ch****'s sake. Thought I may noretreat 02/21/14 03:10:45 PM
#22   all the usual suspects! Ha! You always get Seel 02/21/14 01:46:28 PM
#21   Yup, all the usual suspects caught in the TOB 02/20/14 10:09:53 PM
#20   Hmmmm? Interesting. Must look further. I own a TheDane 02/18/14 07:13:46 PM
#19   Well...we know where somebody's mind is tonight! Take Seel 02/11/14 10:15:58 PM
#18   Anyone knows why this is on the grey sheets? Lilpunch01 02/11/14 02:31:01 PM
#17   IMMVF, prefer not to post my article...in the Gratefullife 02/11/14 11:34:32 AM
#16   Hi Gratefull... Ovidius 02/11/14 03:25:38 AM
#15   WUZZZZZZZZZZZZUP SEEL ! BTW, I'm the CEO and WILD_4_IPIX 02/10/14 06:29:15 PM
#14   Wild in wild form! Always makes me smile! Seel 02/10/14 06:21:01 PM
#13   I think it's all about the grey thing Seel 02/10/14 06:20:23 PM
#12   Next time I will not mention articles until Gratefullife 02/10/14 12:48:12 PM
PostSubject